Language

News topic

Expected end: Anfang November 2026

All current shortage notices related to Expected end: Anfang November 2026, structured by product, country, active ingredient and reporting period.

10 notices

← All shortages

Denmark

Zyprexa 10 mg pulver til injektionsvæske, opløsning (2care4)

Active ingredient: nicht angegeben

View notice details →
Denmark

Lamzede 10 mg pulver til infusionsvæske, opløsning

Active ingredient: nicht angegeben

View notice details →
Denmark

Verorab 3,25 IE pulver og solvens til injektionsvæske, suspension, fyldt injektionssprøjte

Active ingredient: nicht angegeben

View notice details →
Denmark

Abdomin Junior Neutral pulver til oral opløsning, breve (30 stk.)

Active ingredient: Kaliumchlorid, macrogol 3350, natriumchlorid og natriumhydrogencarbonat

View notice details →
Denmark

Pneumovax injektionsvæske, opløsning i fyldt injektionssprøjte (Abacus Medicine)

Active ingredient: Pneumokok polysaccharid serotype 1, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 2, 20, 22F, 23F, 3, 33F, 4, 5, 7F, 8, 9N og 9V

View notice details →
Denmark

Fixopost 50 mikrogram/ml+5 mg/ml øjendråber, opløsning, enkeltdosisbeholder (Thea Nordic AB)

Active ingredient: Latanoprost, timolol

View notice details →
Denmark

Ryzodeg 100 Flextouch 100 E/ml injektionsvæske, opløsning i fyldt pen

Active ingredient: Insulin aspart; insulin degludec

View notice details →
Denmark

Osmohale inhalationspulver, hård kapsel

Active ingredient: Mannitol

View notice details →

Plan supply. Connect sourcing and warehousing.

For pharmacies, wholesalers and manufacturers: choose the service matching your operational need.